BW Forsyth Partners takes majority stake in FLOW TECHNOLOGY

This operation formalizes the strategic partnership and capital injection initiated by BW Forsyth Partners into Flow Technology, securing a comprehensive corporate handover from the target's historical Owner, Tim Murphy. Announced on September 7, 2026, this cross-border financial transaction structurally integrates the Irish engineering specialist into the American sponsor's broader industrial portfolio, although the precise monetary terms of the transaction remain strictly undisclosed. To orchestrate this multijurisdictional equity agreement, the selling shareholders mandated Clearwater Ireland to act as the exclusive sell-side Corporate Finance advisor, supported by legal counsel from Wallace Corporate Counsel and supplementary transaction execution assistance from Frame International, KTA, and Forvis Mazars. Conversely, the acquiring financial institution retained the investment banking services of CMD Global Partners to navigate the buy-side financial engineering and structure the final investment framework. The core strategic thesis driving this external investment focuses explicitly on financing immediate capacity expansion across the United States and European markets to meet surging institutional demand for specialized biopharmaceutical manufacturing infrastructure. Having recently secured two major contracts supporting the domestic capacity expansion of leading global biopharmaceutical manufacturers in the United States, the acquired entity required institutional backing to scale its complex project execution capabilities. The acquiring fund intends to leverage this newly secured platform to directly support pharmaceutical companies investing heavily in localized supply chains and advanced manufacturing technologies. Furthermore, the integration blueprint outlines a formalized collaboration pathway with the buyer's existing portfolio company, Machine Solutions, Inc. By systematically combining their respective technical and manufacturing expertise, the unified entities are optimally positioned to deliver comprehensive process infrastructure to producers of next-generation therapies. Under the agreed governance structure, the newly partnered platform will continuously operate under its existing executive leadership team, maintaining strict operational continuity while directly accessing the new parent company's extensive financial resources to pursue global commercial opportunities.